Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Kalén, Mattias ^a   Heikura, Tommi ^b   Karvinen, Henna ^b   Nitzsche, Anja ^a   Weber, Holger ^c   Esser, Norbert ^c   Ylä Herttuala, Seppo ^b   Hellström, Mats ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c PROQINASE GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; VASCULOTROPIN A; ENZYME INHIBITOR; SECRETASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD FLOW; BLOOD VESSEL OCCLUSION; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENDOLEAK; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; MOUSE; NONHUMAN; SKELETAL MUSCLE; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BLOOD VESSEL; DRUG ANTAGONISM; GROWTH, DEVELOPMENT AND AGING; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; RABBIT;

MUS; ORYCTOLAGUS CUNICULUS;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BLOOD VESSELS; ENZYME INHIBITORS; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79954995855     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018709     Document Type: Article

References (49)

1. Grothey A, Galanis E, (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507-518.
2. Ivy SP, Wick JY, Kaufman BM, (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6: 569-579.
3. Schilsky RL, (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9: 363-366.
4. Schrama D, Reisfeld RA, Becker JC, (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147-159.
5. Turk B, (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
6. Artavanis-Tsakonas S, Rand MD, Lake RJ, (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
7. Kopan R, Ilagan MX, (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233.
8. Miele L, Golde T, Osborne B, (2006) Notch signaling in cancer. Curr Mol Med 6: 905-918.
9. Niessen K, Karsan A, (2008) Notch signaling in cardiac development. Circ Res 102: 1169-1181.
10. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, et al. (1991) TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661.
11. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, et al. (2007) The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 67: 5611-5616.
12. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
13. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, et al. (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445: 776-780.
14. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, et al. (2007) Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134: 839-844.
15. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, et al. (2007) Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 104: 3219-3224.
16. Siekmann AF, Lawson ND, (2007) Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 445: 781-784.
17. Suchting S, Freitas C, le Noble F, Benedito R, Breant C, et al. (2007) The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A 104: 3225-3230.
18. Hellstrom M, Phng LK, Gerhardt H, (2007) VEGF and Notch signaling- The yin and yang of angiogenic sprouting. Cell, Adhesion & Migration 1: 133-136.
19. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, et al. (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5: 168-177.
20. Masuda S, Kumano K, Suzuki T, Tomita T, Iwatsubo T, et al. (2009) Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Sci 100: 2444-2450.
21. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, et al. (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087.
22. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, et al. (2007) Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109: 4753-4760.
23. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, et al. (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464: 1052-1057.
24. Thurston G, Noguera-Troise I, Yancopoulos GD, (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7: 327-331.
25. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, et al. (2008) Rational targeting of Notch signaling in cancer. Oncogene 27: 5124-5131.
26. Kopan R, Ilagan MX, (2004) Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 5: 499-504.
27. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ, (2007) Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 110: 278-286.
28. Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, et al. (2010) Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 70: 2476-2484.
29. Luistro L, He W, Smith M, Packman K, Vilenchik M, et al. (2009) Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69: 7672-7680.
30. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, et al. (2010) Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 9: 1618-1628.
31. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, et al. (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278: 46107-46116.
32. Korff T, Augustin HG, (1999) Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112 (Pt 19): 3249-3258.
33. Rissanen TT, Korpisalo P, Karvinen H, Liimatainen T, Laidinen S, et al. (2008) High-resolution ultrasound perfusion imaging of therapeutic angiogenesis. JACC Cardiovasc Imaging 1: 83-91.
34. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032-1037.
35. High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH, et al. (2008) Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc Natl Acad Sci U S A 105: 1955-1959.
36. Nakajima M, Yuasa S, Ueno M, Takakura N, Koseki H, et al. (2003) Abnormal blood vessel development in mice lacking presenilin-1. Mech Dev 120: 657-667.
37. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF, (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11: 109-119.
38. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, et al. (2005) Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur J Pharmacol 514: 1-15.
39. Petit A, Pasini A, Alves Da Costa C, Ayral E, Hernandez JF, et al. (2003) JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo. J Neurosci Res 74: 370-377.
40. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 12876-12882.
41. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, et al. (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463: E6-7.
42. Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, et al. (2008) Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 48: 607-616.
43. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, et al. (2009) Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15: 50-58.
44. Aste-Amezaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, et al. (2010) Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 5: e9094.
45. Korpisalo P, Karvinen H, Rissanen TT, Kilpijoki J, Marjomaki V, et al. (2008) Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ Res 103: 1092-1099.
46. Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Orden MR, et al. (2005) Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation 112: 3937-3946.
47. Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, et al. (2003) Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. Faseb J 17: 100-102.
48. Hewitt CD, Innes DJ, Savory J, Wills MR, (1989) Normal biochemical and hematological values in New Zealand white rabbits. Clin Chem 35: 1777-1779.
49. Ypsilantis P, Politou M, Mikroulis D, Pitiakoudis M, Lambropoulou M, et al. (2007) Organ toxicity and mortality in propofol-sedated rabbits under prolonged mechanical ventilation. Anesth Analg 105: 155-166.